AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11566624
Drug: Neutralising anti-TNF-alpha
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralising anti-TNF-alpha monoclonal antibody
Trial: 8181202
Drug: Cotinine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotinine (30 mg) intravenously
Trial: 3651943
Drug: One-dose regimen
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose regimen of trivalent inactivated whole-virion influenza vaccine (0.5 ml, containing 15 micrograms of hemagglutinin of each antigen)
Trial: 3651943
Drug: Two-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose regimen of trivalent inactivated whole-virion influenza vaccine (0.5 ml, second dose administered 8 weeks after the first)
Trial: 29990851
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg) based on total body weight (TBW)
Trial: 29990851
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg) based on lean body weight (LBW)
Trial: 26116635
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (kinesitherapy and electrotherapeutic procedures) including medicamentous therapy, walking exercises beyond the pain threshold, dynamic low‐burden kinesi exercises, interference therapy, diadynamic therapy, and electromagnetic field.
Trial: 26116635
Drug: Conventional non‐operative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non‐operative treatment including medicamentous therapy and walking exercises.
Trial: 17488793
Drug: rhGH (0.46
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.46 mg/kg.wk) in daily sc injections
Trial: 17488793
Drug: No rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rhGH therapy
Trial: 15061962
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg/kg, 2 mg/kg, and 3 mg/kg)
Trial: 15061962
Drug: Midazolam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.2 mg/kg, 0.3 mg/kg, and 0.4 mg/kg)
Trial: 15061962
Drug: Etomidate (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.15 mg/kg, 0.3 mg/kg, and 0.4 mg/kg)
Trial: 9745140
Drug: Micanol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micanol monotherapy
Trial: 9745140
Drug: Micanol in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micanol in combination with UVB phototherapy
Trial: 20127530
Drug: Central neuraxial
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central neuraxial blockade (anesthetic dose)
Trial: 20127530
Drug: Central neuraxial
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central neuraxial blockade (analgesic dose)
Trial: 18716414
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg) and folic acid (10 mg/day) for 6 weeks
Trial: 18716414
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and placebo for 6 weeks
Trial: 12455569
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) therapy 6,000 U/week for 6 months
Trial: 25040164
Drug: Clinic control
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic control (CC)
Trial: 17785672
Drug: Brivaracetam 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 10, 20, 40, or 80 mg
Trial: 17785672
Drug: Brivaracetam 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 80 mg
Trial: 15553820
Drug: hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hormone replacement therapy (HRT)
Trial: 10207795
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy (10 MU/m2 of lymphoblastoid interferon alfa 3 times per week for 12 weeks)
Trial: 2205259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5-fluorouracil (5-FU) and plasma perfusion (PP) over protein A-Sepharose (group A)
Trial: 2037387
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5-FU and PP over sepharose (group B)
Trial: 31634603
Drug: Pharmacomechanical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacomechanical therapy
Trial: 29733435
Drug: Imarikiren 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imarikiren 80 mg (nonelderly)
Trial: 29733435
Drug: Imarikiren 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imarikiren 160 mg (nonelderly)
Trial: 29733435
Drug: Imarikiren 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imarikiren 80 mg (elderly)
Trial: 23452670
Drug: Volumetric arc
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volumetric arc therapy (VMAT)
Trial: 20975107
Drug: Dextrose meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose meal (2.25 g/kg)
Trial: 20975107
Drug: Maltodextrin meal
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin meal (2.25 g/kg)
Trial: 14634942
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL bupivacaine 0.5%
Trial: 14634942
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL saline 0.9%
Trial: 10390665
Drug: granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: granisetron 40 mg kg‐1
Trial: 10390665
Drug: perphenazine 70
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: perphenazine 70 mg kg‐1
Trial: 8877766
Drug: Adenine arabinoside
RxNorm normalized name: Adenine
DrugBank: Adenine (DB00173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenine arabinoside 5'‐monophosphate (ARA‐AMP), 5 mg/kg/day during 7 weeks
Trial: 6357595
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg epirizole for 14 days
Trial: 6357595
Drug: 3000 mg
RxNorm normalized name: talc 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg ASA
Trial: 6357595
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg epirizole
Trial: 2859465
Drug: Calcium bis
RxNorm normalized name: calcium bis(3-phenylpyruvate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium bis acetyl homotaurine (Ca AOTA, 25 mg/kg/day)
Trial: 31088531
Drug: Video intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video intervention therapy (VIT) consisting of four modules with one video-recorded play session and one VIT session per week.
Trial: 31088531
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus weekly play sessions (Control group).
Trial: 22482940
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (3 mg/m² on days 1, 4, and 7 during induction and day 1 of each of the two consolidation chemotherapy courses)
Trial: 18929703
Drug: Aggressive lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aggressive lovastatin treatment (LDL cholesterol target <85 mg/dl)
Trial: 18929703
Drug: Moderate lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate lovastatin treatment (LDL cholesterol target <140 mg/dl)
Trial: 8641743
Drug: Bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 5 mg once daily
Trial: 1298186
Drug: SIN-1 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIN-1 (1 mg)
Trial: 10232493
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (5 mg)
Trial: 6237916
Drug: Nicorandil 15
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 15 mg
Trial: 6237916
Drug: Nicorandil 30
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 30 mg
Trial: 20093512
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 5 mg
Trial: 27009317
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy skills training
Trial: 17150247
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and cisplatin treatment in Stage III/IV patients with BMI ≥ 40
Trial: 17150247
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and cisplatin treatment in patients with higher BMI
Trial: 17150247
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and cisplatin treatment
Trial: 16398437
Drug: Acupoint electro-superconducting
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint electro-superconducting therapy with Chinese herbal drugs contained pad
Trial: 12480356
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg single-dose mifepristone
Trial: 12480356
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg single-dose levonorgestrel
Trial: 12480356
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 0.75 mg levonorgestrel given 12 hours apart
Trial: 9892860
Drug: Apomorphine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (0.75 mg s.c.)
Trial: 27067836
Drug: Andrew's manoeuvre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrew's manoeuvre (four-hands CC) during DA-CPR
Trial: 25902891
Drug: Naloxone, opioid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone, opioid, and saline admixture (NOSA) containing 12 μg naloxone per 1 mg morphine per 1 mL normal saline.
Trial: 25902891
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving morphine only.
Trial: 14550427
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg/day) for 6 weeks
Trial: 28806348
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 200 mg/day
Trial: 9165857
Drug: Home support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home support from a trained oncology nurse during treatment
Trial: 9165857
Drug: Visits after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visits after treatment
Trial: 3927958
Drug: Nicardipine 40
RxNorm normalized name: niCARdipine 40 mg/200 mL-D5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 40 mg thrice daily
Trial: 31945816
Drug: GCWB104 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCWB104 (300 mg containing 125 mg of Flos Lonicera extract, twice daily)
Trial: 31945816
Drug: Placebo (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (300 mg, twice daily)
Trial: 30293770
Drug: LY3298176 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3298176 (1 mg)
Trial: 30293770
Drug: LY3298176 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3298176 (5 mg)
Trial: 30293770
Drug: LY3298176 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3298176 (10 mg)
Trial: 30293770
Drug: LY3298176 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3298176 (15 mg)
Trial: 17975386
Drug: Early renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early renal replacement therapy
Trial: 24998258
Drug: Delayed renal
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed renal replacement therapy
Trial: 7848024
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg once daily
Trial: 21088400
Drug: Relaxin (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxin (intravenous doses)
Trial: 19029516
Drug: Subcutaneous IGF-1
RxNorm normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous IGF-1 (0.05 mg/kg body weight, twice daily)
Trial: 10827388
Drug: Local delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local delivery of 5000 U heparin infused into the arterial wall
Trial: 10827388
Drug: Intraluminal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal delivery of 5000 U heparin administered to the coronary artery lumen
Trial: 8846277
Drug: Patient Controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Controlled Analgesia (PCA) using morphine
Trial: 24996988
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine infusion
Trial: 8198941
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg kg‐1 intravenous lignocaine
Trial: 8198941
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg kg‐1 intravenous lignocaine (fed)
Trial: 8198941
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg kg‐1 intravenous lignocaine (fasted)
Trial: 3332678
Drug: Topical benzyl
RxNorm normalized name: benzyl alcohol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzyl alcohol (BA)
Trial: 26358690
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg oral dose
Trial: 23587538
Drug: Standardized uterosacral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized uterosacral ligament suspension colpopexy (USLSC)
Trial: 26860492
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound therapy
Trial: 19494795
Drug: NGX-4010 capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NGX-4010 capsaicin patch (640 microg/cm2) applied for 60 minutes
Trial: 19494795
Drug: NGX-4010 capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NGX-4010 capsaicin patch (640 microg/cm2) applied for 90 minutes
Trial: 19494795
Drug: NGX-4010 capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NGX-4010 capsaicin patch (640 microg/cm2) applied on feet
Trial: 19494795
Drug: NGX-4010 capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NGX-4010 capsaicin patch (640 microg/cm2) with larger treatment areas
Trial: 17185118
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine (36 mg lidocaine + 18 mug epinephrine)
Trial: 17185118
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus meperidine with epinephrine (36 mg lidocaine + 18 mug epinephrine + 36 mg meperidine + 18 mug epinephrine)
Trial: 15794456
Drug: 18% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18% carbamide peroxide paint-on gel
Trial: 14700480
Drug: Oral bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral bexarotene 300 mg/m2/day
Trial: 14700480
Drug: Oral bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral bexarotene 600 mg/m2/day
Trial: 14700480
Drug: Placebo (prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (prior chemotherapy responders)
Trial: 14700480
Drug: Oral bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral bexarotene 300 mg/m2/day (prior chemotherapy responders)
Trial: 14700480
Drug: Oral bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral bexarotene 600 mg/m2/day (prior chemotherapy responders)
Trial: 9643407
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant therapy (radiotherapy and/or systemic chemotherapy)
Trial: 2789438
Drug: 15% polyvinylpyrrolidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% polyvinylpyrrolidone (PVP) solution
Trial: 2789438
Drug: 20% polyvinylpyrrolidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% polyvinylpyrrolidone (PVP) solution
Trial: 28339098
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with concurrent cediranib and continued as maintenance
Trial: 28339098
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy only
Trial: 21060206
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) administration
Trial: 21060206
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no EPO administration)
Trial: 16604826
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg daily for 5 days)
Trial: 16604826
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (100 mg daily for 5 days)
Trial: 10748791
Drug: Beta-blocker treatment
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker treatment (Bisoprolol)
Trial: 2123239
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with penicillin V (10-day course starting at diagnosis)
Trial: 2123239
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with penicillin V (10-day course starting after 48 hours)
Trial: 6104858
Drug: tiapride (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiapride (300 mg daily for 3-4 weeks)
Trial: 6104858
Drug: floctafenine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: floctafenine (200 mg daily for 3-4 weeks)
Trial: 20638874
Drug: Melatonin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin infusion (50 mg IV during surgery) and oral melatonin (10 mg for 3 nights post-surgery)
Trial: 20638874
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion and oral placebo
Trial: 15746463
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg per day
Trial: 10480207
Drug: Vigabatrin (GVG)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (GVG) therapy
Trial: 2300680
Drug: Moclobemide (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (100, 200, and 300 mg)
Trial: 2300680
Drug: Deprenyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl (10 mg)
Trial: 31942627
Drug: Darunavir/ritonavir 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir 800/100 mg q24h with rifampicin, escalated to darunavir/ritonavir 1600/200 mg q24h and 800/100 mg q12h.
Trial: 31942627
Drug: Darunavir/ritonavir adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir adjusted doses with rifampicin.
Trial: 22572824
Drug: Long-acting octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting octreotide (Sandostatin LAR®) depot 30 mg intramuscularly every month
Trial: 20500927
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg quercetin/d
Trial: 20500927
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg quercetin/d
Trial: 17971108
Drug: Nicorette polacrilex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorette polacrilex gum (6 mg)
Trial: 12433727
Drug: Selenium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-enriched yeast supplementation (247 micro g selenium/day)